CASSINI and AVERT - future role of NOACs for VTE prevention in cancer patients?

Vasa. 2020 Apr;49(3):247-248. doi: 10.1024/0301-1526/a000854.
No abstract available

MeSH terms

  • Administration, Oral
  • Anticoagulants / adverse effects
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / drug therapy
  • Rivaroxaban / therapeutic use
  • Venous Thromboembolism* / diagnosis
  • Venous Thromboembolism* / drug therapy
  • Venous Thromboembolism* / prevention & control

Substances

  • Anticoagulants
  • Rivaroxaban